Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Vastra Gotaland Region
Seagen Inc.
KaliVir Immunotherapeutics
IDEAYA Biosciences
iOnctura
Sotio Biotech Inc.